Radioactive One-Two punch takes on returning prostate cancer
NCT ID NCT07150715
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial is testing two radioactive drugs, 225Ac-PSMA-617 and 177Lu-PSMA-617, combined with precise radiation therapy for prostate cancer that has returned and spread to a few spots in the body. The drugs target a protein on cancer cells and deliver radiation to kill them. The study will compare which drug works better with radiation to control the cancer and improve how long patients live without the disease getting worse.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Radioactive drugs (225Ac-PSMA-617 or 177Lu-PSMA-617) plus stereotactic body radiotherapy
What this could lead to
If successful, this could offer a more effective way to control recurrent prostate cancer that has spread to a few sites, potentially delaying the need for hormone therapy.
What could go wrong
This is a phase II trial with only 107 participants, so results are preliminary. The radioactive drugs can cause side effects like low blood counts and dry mouth, and the treatment may not work for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OLIGOMETASTATIC PROSTATE ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UCLA / Jonsson Comprehensive Cancer Center
RECRUITINGLos Angeles, California, 90095, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••